Moscow, 11 May, 2011 — JSC Pharmstandard (LSE: PHST, RTS: PHST RU) invites its shareholders/holders to its annual general meeting of shareholders (hereinafter: the «AGM») at 12.00 a.m. Moscow time on 30 June 2011. The record date for the AGM is 11 May 2011.

AGM will be held at the following address:
Pharmstandard conference room.
Likhachevskiy drive 5B, Dolgoprudniy, Moscow Region, Russia, 141700
Registration of participants will begin at 11:15 a.m. Moscow time.

There are following key items will be discussed at the AGM:
1. Adoption of the financial statements for the year 2010 and 2010 annual report; allocation of profit and losses of the company based on year 2010 financial results.
2. Dividends for the year 2010.
3. Election of the Board of Directors.
4. Election of Audit Committee.
5. Appoint independent audit company for the year 2011.

Contacts:
OJSC Pharmstandard
Ilya Krylov
Tel: +7 495 970 0030 ext 2416
E-mail: ir@pharmstd.ru
www.pharmstd.ru

About Pharmstandard:
Pharmstandard is the leader of Russian pharmaceutical industry in R&D and production of the medicinal products. Pharmstandard became ¹ 2 among all pharmaceutical companies represented on commercial market in Russia. Market share of Pharmstandard reached 4.2% in 2010. ¹

The Company is the leader measured by sales in the whole Russian pharmaceutical market in the year 2010. Since 2007 Pharmstandard keeps its leading position in commercial segment and remains strong leader among the domestic pharmaceutical company-manufacturers. ¹

Pharmstandard became the winner of the national business award «Company of the Year 2010» according to RBC². During the tenth anniversary of «Platinum Ounce 2009», the open competition among professionals of pharma business, Pharmstandard was awarded in the nominations for «The Company of the Year — the Russian pharmaceutical products manufacturer» and «The Company of Decade — the Russian pharmaceutical products manufacturer».

Pharmstandard operates three modern pharmaceutical manufacturing facilities: JSC «Pharmstandard-Leksredstva» in Kursk, JSC «Pharmstandard-UfaVITA» in Ufa, JSC «Pharmstandard-Tomskhimpharm» in Tomsk and medical equipment factory JSC «TZMOI» in Tyumen.

The Company has invested approximately RUR 3 billion RUR in modernization and development of production capacities reaching more than 1,35 bln units per year. All the production facilities fully comply with Russian manufacturing standards. Six production lines of JSC «Pharmstandard-Leksredstva» meet EU GMP requirements.
Pharmstandard portfolio includes over 250 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer. More than 100 products offered by Pharmstandard are included in the List of Vital and Essential Pharmaceuticals.

Among our market-leading brands are Arbidol^®, Complivit^®, Pentalgin^®, Flucostat^®, Phosphogliv^®, Amixin^® and Afobazol^®. Antiviral product «Arbidol» was awarded for «Platinum ounce 2009» in the nominations «OTC Product of the Year» and «OTC Product of Decade». Pentalgin^® has been granted «BRAND #1 IN RUSSIA» award for 2009 in analgesics category.

In 2004-1H2010, we developed and introduced over 40 new pharmaceutical products in close collaboration with the leading scientific centers of Russia. Pharmstandard is the partner of the joint venture biotechnological project «Generium» in order to develop and manufacture innovative biological products within the state program of import substitution.

Pharmstandard became a public company in 2007 by offering to the public 27.6% of its share capital in the form of GDR on the London Stock Exchange (LSE) and 18.1% of its share capital in the form of ordinary shares on two local stock exchanges (RTS, MICEX). Approximately 54.3%of voting shares of OJSC «Pharmstandard» are held by «Augment Investments Limited».

www.pharmstd.ru

1 Pharmexpert (CMR) 2010 market data.
² The annual national business award 'Company of the Year' is organized by RBK Holdings.